Plain-English translation of NCT06766825 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a medication called plitidepsin can help people who continue to experience bothersome symptoms months after having COVID-19 (often called long COVID). The medication works in three ways: it may fight lingering virus, reduce inflammation in the body, and prevent herpes virus reactivation—all of which may contribute to long COVID symptoms. About 90 patients will be randomly assigned to receive either the medication or a placebo (a fake treatment) over several months.
Many people suffer from long-lasting symptoms after COVID-19 that significantly impact their daily life, and there is currently no proven treatment. This study exists to see whether this medication, which has shown promise in lab studies, could offer relief for these patients.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly placed into one of three groups: one receiving the medication four times, one receiving placebo first then the medication, or one receiving placebo throughout. You will receive intravenous infusions (through an IV line) on four different treatment periods spread over about 6 weeks (Days 1–3, 15–17, 29–31, and 43–45). Each infusion takes about 1 hour. You will have follow-up visits and safety checks throughout the study to monitor how you respond to the treatment.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
Spain